Assessment of cell-free levels of iron and copper in patients with Friedreich’s ataxia
- 27 Downloads
Friedreich’s ataxia (FRDA), a progressive neurodegenerative disorder caused by trinucleotide (GAA) repeat expansion in frataxin (fxn) gene which results in decreased levels of frataxin protein. Insufficient frataxin levels leads to iron and copper deposits in the brain and cardiac cells. A total of hundred and twenty patients, suspected of FRDA were screened for the (GAA) repeats in the fxn gene and only confirmed patients (n = 25) were recruited in the study. The total Iron and total copper concentrations were measured in blood plasma using Nitro PAPS and Dibrom PAESA method, respectively both in patients and age, sex matched healthy controls. The iron levels mean ± SD (6.2 ± 3.8) in plasma of FRDA patients were found to be significantly decreased as compared to healthy controls mean ± SD (15.2 ± 4.2). A similar trend was observed in case of plasma copper levels in FRDA patient (8.15 ± 4.6) as compared to controls (17.5 ± 3.40). Present results clearly prove abnormal distribution of extra-cellular iron in FRDA patients, which is in accordance with the well established fact of intracellular iron overload, which is the key feature of the pathogenesis of this disease. This can be of importance in understanding the pathophysiology of the disease in association with frataxin/iron. It appears that intracellular sequestration of trace metals in FRDA patients (due to low frataxin) results in their sub-optimal levels in blood plasma (extra-cellular) an observation that can find prognostic application in clinical trials.
KeywordsFriedreich’s ataxia (FRDA) Neurodegenerative disorder Mitochondrial iron accumulation Plasma iron and copper ROS
We thank all the FRDA patients and healthy volunteers for their participation. The authors would like to thank Dr. Ashok Sharma (Dept of Biochemistry, AIIMS) for kind permission to use the Bioanalyzer for trace metal analysis. The financial support from the intra-mural grant from All India Institute of Medical Sciences (AIIMS) New Delhi (A-497) is gratefully acknowledged.
MRR: Conceived the idea, designed the experiments and wrote the manuscript. AKS and SG: Provided the FRDA patient samples. DP: Executed the experiments, acquired the raw data and wrote the first draft of the manuscript. All authors were involved in interpreting the data. All authors approved the final manuscript.
The financial support from the intra-mural grant from AIIMS, New Delhi (A-497) is gratefully acknowledged. DP received Research Fellowship from Indian council of Medical Research, No 3/1/3/JRF-2012).
Compliance with ethical standards
Conflict of interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
- Becker EM, Greer JM, Ponka P, Richardson DR (2002) Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood. https://doi.org/10.1182/blood.V99.10.3813 Google Scholar
- Puccio H, Simon D, Cossée M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M (2001) Mouse models for friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. https://doi.org/10.1038/84818 Google Scholar
- Whitnall M, Rahmanto YS, Sutak R, Xu X, Becker EM, Mikhael MR, Ponka P, Richardson DR (2008) The MCK mouse heart model of Friedreich’s ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Nat Acad Sci USA. https://doi.org/10.1073/pnas.0804261105 Google Scholar